Sedia™ BED HIV-1 Incidence EIA

CDC Approved Sedia™ BED HIV-1 Incidence EIA to Determine Recency of Infection and Estimate HIV-1 Incidence.
Cat. No. 1000 |
Sedia™ BED HIV-1 Incidence EIA, 192 Tests |
Cat. No. 1001 |
Sedia™ BED HIV-1 Incidence EIA Dried Blood Spot Controls Pack, 20 Cards (click here for more information) |
- More 10X Washer Buffer Concentrate is provided (200 mL)
- 10X Wash Buffer Concentrate is now interchangeable and compatible with 10X Wash Buffer Concentrate of Sedia™ HIV-1 LAg-Avidity EIA for our customers who wish to use both assays in their plate washer equipment.
- Improved stability of diluted (1X) Wash Buffer (stable at 2-30ºC for up to 1 month).
- More versatile EIA Assay Plate Design (no longer limited to 8-well strips, user can run any multiple of single wells).
U.S. CDC Approved
Each Sedia™ BED HIV-1 Incidence EIA lot is tested by both Sedia's Quality Control Department and by the U.S. Centers for Disease Control prior to market release.
Certification of U.S. CDC testing and approval is provided with each assay kit.
Each Sedia™ BED HIV-1 Incidence EIA lot is tested by both Sedia's Quality Control Department and by the U.S. Centers for Disease Control prior to market release.
Certification of U.S. CDC testing and approval is provided with each assay kit.
Use of the Sedia™ BED HIV-1 Incidence EIA in the U.S.
The SEDIA™ BED HIV-1 Incidence EIA is for Research Use Only and Not for Use in Diagnostic Procedures. Users of the Sedia™ BED HIV-1 Incidence EIA based in the U.S. are required to complete and submit a Certification Regarding Research Use (download here) prior to shipment of the product certifying that use of the product will be used for research use only in compliance with FDA regulations.